Substance P/Neurokinin1 Receptor Antagonists

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Texas Vendor Drug Program formulary coverage.

• Revision history
  • October 21, 2022; September 2020; September 2018; September 2016; May 2015; August 2013; June 2013; September 2011; October 2009; February 2006; January 2006
• Initially developed
  • Dec. 2003